Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06628362 · ClinicalTrials.gov registry record · Phase 2
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
A Phase 2 study of Type 2 Diabetes Mellitus (T2DM) and Overweight or Obese, sponsored by Carmot Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT06628362 is a Phase 2 study of Type 2 Diabetes Mellitus (T2DM) and Overweight or Obese that is active but no longer recruiting, run by Carmot Therapeutics. The registered enrollment target is 360 participants, below the 507-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06628362, a Phase 2 study of Type 2 Diabetes Mellitus (T2DM) and Overweight or Obese, is active but no longer recruiting, sponsored by Carmot Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CT-388
Study Locations (20)
Florida
- Flourish Research - Boca Raton - Boca Raton
- Tampa Bay Medical Research - Clearwater
- K2 Medical Research, LLC - Maitland - Maitland
- K2 Medical Research, LLC - Orlando - Maitland
- Flourish Research Acquisition, LLC - Miami
- K2 Medical Research, LLC - South Orlando - Orlando
- Aging Well Associates - St. Petersburg
- K2 Medical Research Tampa - Tampa
- K2 Summit Research - The Villages
California
- AMCR Institute - Escondido
- Ark Clinical-Fountain Valley - Fountain Valley
- Orange Country Research Center - Lake Forest
- Ark Clinical Research - Long Beach
- Catalina Research Institute, LLC - Montclair
- Asclepes Research Centers - Sherman Oaks
- Encompass Clinical Research - Spring Valley
Alabama
- Central Alabama Research - Birmingham
- University of Alabama at Birmingham (UAB) - Birmingham
- Lakeview Clinical Research, LLC - Guntersville
Arizona
- Yuma Clinical Trials - Yuma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06628362
The ClinicalTrials.gov registry entry for NCT06628362 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 507-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (29% lower). The listed sponsor is Carmot Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes Mellitus (T2DM) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06628362 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06628362 about?
NCT06628362 is a clinical study titled "A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus". This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT06628362?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2024-11-21. Estimated completion is 2026-11-30.
What conditions does trial NCT06628362 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus (T2DM), Overweight or Obese.
What interventions are being tested in trial NCT06628362?
The interventions under investigation include: Placebo (DRUG), CT-388 (DRUG).
Who is sponsoring clinical trial NCT06628362?
This trial is sponsored by Carmot Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06628362 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus (T2DM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
ACTIVE NOT RECRUITING · Phase 2
-
Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video Observation
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.